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The mammalian protein MBD4 contains a methyl-CpG binding domain and can
enzymatically remove thymine (T) or uracil (U) from a mismatched CpG site
in vitro. These properties suggest that MBD4 might function in vivo to minimize
the mutability of 5-methylcytosine by removing its deamination product from
DNA. We tested this hypothesis by analyzingMbd4/ mice and found that the
frequency of of C3 T transitions at CpG sites was increased by a factor of three.
On a cancer-susceptible ApcMin/ background, Mbd4/ mice showed accel-
erated tumor formation with CpG 3 TpG mutations in the Apc gene. Thus
MBD4 suppresses CpG mutability and tumorigenesis in vivo.
Deamination of 5-methylcytosine (m5C) to T
at CpG sites is probably the single most
important cause of point mutations in hu-
mans, accounting for more than 20% of all
base substitutions that give rise to genetic
disease (1). Estimates based on the in vitro
deamination rate of m5C (2) suggest that
approximately four m5C residues deaminate
per diploid genome per day in the germ line.
It is likely that many of the resulting mis-
matches are repaired, but appropriate repair
must take into account that the incorrect base
at the T:G mismatches is invariably T, not G.
Two mismatch-specific T glycosylases that
accomplish this discrimination in vitro have
been discovered. Both thymine DNA glyco-
sylase [TDG; (3, 4)] and MBD4 (5, 6) can
specifically remove T from a T-G mismatch
within a CpG context without cleaving the
DNA strand. This study concerns MBD4,
which contains a COOH-terminal glycosy-
lase domain (7, 8) and an NH2-terminal meth-
yl-CpG binding domain [MBD; (7)]. The
MBD binds to symmetrically methylated
CpG sites but has a higher affinity in vitro for
m5CpG/TpG mismatches, which arise due to
deamination at methyl-CpG (5). Neither
TDG nor MBD4 has been tested for its effect
on mutations in vivo.
To investigate whether MBD4 suppresses
the mutability of methylated CpG sites in
vivo we generated mice bearing a mutated
Mbd4 gene by means of targeted allele re-
placement in embryonic stem cells (9). The
mutated allele contained a cassette within
intron 1 containing a splice acceptor and
polyadenylation signal. Mice homozygous
for this allele were viable and fertile. North-
ern blot (10) and reverse transcriptase–poly-
merase chain reaction (RT-PCR) analyses
confirmed that MBD4 expression was less
than 0.1% of the wild-type level in tissues
from homozygous-mutant mice (fig. S1). We
refer to this allele as Mbd4– throughout this
study.
To determine whether MBD4 deficiency
leads to an increase in mutations at CpG sites,
we crossed mice with the “Big Blue” reporter
locus, comprising 40 head-to-tail copies of a
recoverable lambda transgene (11), onto the
Mbd4/ background and measured in vivo
mutation frequencies at the  cII locus (12).
Bisulfite sequencing (9) of the cII locus from
both wild-type and Mbd4/ mice showed
that, on average, 95% of the CpG sites in the
cII gene are methylated (Fig. 1A). The fre-
quency of cII mutations in liver and spleen of
105-day-old mice and in spleens of 183-day-
old mice was determined by plating packaged
genomic DNA (9, 12). The total mutant fre-
quency in Mbd4/ mice (6.8  105) was
significantly higher than in wild-type animals
(3.2  105) by a maximum likelihood ratio
test [P  0.0001; Fig. 1B; Table 1; (9)]. This
difference was reduced, but remained statis-
tically significant (P  0.05), when a correc-
tion for the number of independent mutations
was applied [Fig. 1B; (9)]. The true mutation
frequency is likely to lie between the uncor-
rected and corrected values, as correction
may underestimate the real number of inde-
pendent mutational events.
A striking difference between wild-type
and Mbd4/ mice emerged when the spec-
trum of mutations was examined. The most
abundant mutational change in both wild-
type and mutant mice involved CG 3 TA
transitions, but this category was more fre-
quent in Mbd4/ mice than in Mbd4/
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Table 1. Analysis of mutation frequencies at the cII locus of a bacteriophage  transgene in Mbd4/ and
Mbd4/ mice. Numbers of “mutants” were derived from raw counts of mutant plaques. Numbers of
“mutations” were deduced by correcting mutant numbers for likely clonal expansion of a single mutant

















Mbd4/ (3) 105/liver 656,165 15 2.29 15 2.29
Mbd4/ (3) 105/liver 991,900 39 3.93 32 3.23
Mbd4/ (4) 105/spleen 1,340,250 45 3.36 38 2.84
Mbd4/ (4) 105/ spleen 1,201,833 88 7.32 39 3.25
Mbd4/ (1) 183/ spleen 200,500 11 5.49 11 5.49
Mbd4/ (1) 183/ spleen 227,433 38 16.71 27 11.87
R E P O R T S
www.sciencemag.org SCIENCE VOL 297 19 JULY 2002 403
controls (Fig. 1D; corrected data were ana-
lyzed). The difference between wild-type and
Mbd4/ mice could be specifically attribut-
ed to a highly significant 3.3-fold increase in
CG 3 TA transitions at CpG sites (P 
0.0001; Fig. 1D). Other mutation categories,
including CG 3 TA transitions at non-CpG
sites, were not significantly altered by the
absence of MBD4 (P  0.1). The effect on
the overall mutation spectrum was apparent
from the fraction of all point mutations at
CpG (Fig. 1C). In wild-type mice, 28 to 31%
(this study) and 26.9% (13) of point muta-
tions were found to be at CpG, which is
similar to the fraction deduced from human
genetic diseases (23%) (1). In Mbd4/
mice, however, the fraction rose to between
56% (corrected) and 76% (uncorrected).
We next asked whether the increased mu-
tability of Mbd4/ mice led to an increased
incidence of cancer in an in vivo model of
intestinal tumorigenesis. MBD4 is mutated in
26 to 43% of human colorectal tumors that
show microsatellite instability (14, 15), sug-
gesting that loss of MBD4 may contribute to
genome instability (16). To test whether loss
of MBD4 increases tumorigenesis, Mbd4/
mice were made heterozygous for the Min
allele of the adenomatous polyposis coli
gene (ApcMin), which predisposes mice to
the development of spontaneous intestinal
neoplasia (17). Littermates were divided
into (Mbd4/, ApcMin/) and (Mbd4/,
ApcMin/) cohorts and killed when they
became symptomatic for intestinal neopla-
sia (9). Mbd4/ mice showed markedly
reduced survival compared with Mbd4/–
controls (P  0.001, Fig. 2A). Moreover,
whole-mount analysis showed a small but
significant (P  0.01) increase in intestinal
adenoma burden at death in (Mbd4/,
ApcMin/) mice (median  28 tumors)
compared with (Mbd4/–, ApcMin/) mice
(median  14 tumors) (Fig. 2B). Histolog-
ical analysis revealed no morphological




To determine whether the loss of repair
activity at CpG sites contributed to the accel-
erated tumor formation, we analyzed the na-
ture of mutations causing loss of function of
the wild-type Apc allele in intestinal tumors.
On an ApcMin/ background in the absence of
mutagenic challenge, the overwhelming
cause of spontaneous tumors is complete de-
letion (loss of heterozygosity, or LOH) of the
Apc allele (18). In agreement with this, we
found that all 15 Mbd4/– tumors in the large
intestine showed loss of the Apc allele. In
contrast, 15 of 39 tumors (38%) from
(Mbd4/, ApcMin/) mice retained both Apc
alleles (Fig. 2C). Sequencing of part of the
Apc gene (9) in the latter tumors revealed
eight mutations. Five mutations were CpG3
TpG transitions, of which four would cause
Fig. 1. MBD4-deficiency increas-
es the frequency of CG 3 TA
mutations at CpG sites. (A) The
positions of the 22 CpG sites in
the cII gene are indicated by ver-
tical lines. The methylation sta-
tus of 10 clones from Mbd4/
spleen DNA is shown below,
with filled boxes denoting meth-
ylated sites and unfilled boxes
denoting unmethylated sites.
The number of sequenced clones
with identical methylation pat-
terns is indicated on the right,
where it exceeds one. A similar
level of methylation was ob-
served in Mbd4/ mice, and in





mutant plaques (P 
0.0001) and of indi-
vidual mutations (P 
0.05) than wild-type
mice (white bars).
These data sum all
time points and tis-
sues. (C) Increased
percentage of all point
mutations that are




raw and corrected data. (D) Mutational spectra on the Mbd4/ and Mbd4/backgrounds
(corrected data). Mutations at CpG sites in all categories are shaded in black, and the total number
of individual mutations found in each category for each genotype is indicated below the appro-
priate bar.
Fig. 2. MBD4 deficiency accel-
erates intestinal neoplasia on
an ApcMin/ background. (A)
Kaplan-Meier plot showing sig-
nificant (P  0.001, log rank)
reduction in survival of
(Mbd4/, ApcMin/) mice
compared with (Mbd4/–, Apc-
Min/) mice. Solid black line (Mbd4/, ApcMin/) mice (n  17); broken line (Mbd4/, ApcMin/)
mice (n  36). (B) Tumor burden in (Mbd4/–, ApcMin/) and (Mbd4/, ApcMin/) mice at necroscopy.
The median value for each genotype is indicated by a horizontal line in the boxplots. There was a small
but statistically significant increase (Mann-Whitney U test, P  0.01) in tumor number in the
(Mbd4/, ApcMin/) mice. (C) Apc mutations in tumors of the large intestine in (Mbd4/, ApcMin/)
mice. The upper band (Min) is the Hind III-resistant ApcMin PCR product, whereas the lower band (“wild
type”) is the initially wild-type Apc allele, which can be cut by Hind III. Lanes a, nontumor control
samples from intestines of Mbd4/– mice; lanes b, tumors from Mbd4/– mice showed 100% (n  20)
LOH; lanes c, tumors from Mbd4/ mice showed 62% (n  39) LOH, which is significantly less than
Mbd4/– mice (P  0.001, chi-square test). The presence of a weak Apc band in tumors that have lost
this allele is due to unavoidable contamination with nontumor tissue (notably, blood).
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truncation of the APC protein (table S1). The
complete absence of equivalent mutations in
control mice indicates that the suppression of
intestinal tumors by Mbd4 is due at least in
part to suppression of CpG 3 TpG transi-
tions at the endogenous Apc gene.
Our findings clearly implicate MBD4 in the
repair of m5C deamination at methylated CpG
residues, but is it solely responsible for this
repair? If we assume that the in vitro deamina-
tion rate of m5C (5.8  1013/second) (2)
applies in vivo, we predict a C3 T transition
frequency of 1.25  104 at CpG sites in the
cII locus in the absence of repair. The observed
mutation frequency in wild-type mice is 4% of
this calculated value, suggesting that repair of
m5C deamination is about 96% efficient. In
Mbd4/ mice, the CpG to TpG mutation fre-
quency is 1.5  105, suggesting that repair
efficiency has fallen to 88% but remains mod-
erately effective. This approximate calculation
indicates that repair of deaminated m5C is
shared with factors other than MBD4, for ex-
ample, TDG or equivalent activities. In theory,
two independent repair activities that were each
80% efficient could give a combined efficien-
cy of 96%.
Why is m5C a mutational hotspot in spite
of the presence of at least one repair mecha-
nism? One plausible explanation is that the
existence of close to 109 T residues in the
mouse genome, each one losing its base pair-
ing with A many times per second (19),
renders enzymes that remove unpaired T po-
tentially mutagenic. With respect to C deami-
nation, this problem is thought to have been
solved by replacing U with T in the ancestral
RNA-derived genome, so that the deamina-
tion product of C became easily distinguish-
able from a normal DNA base (20). All
known U:G mismatch glycosylases are inert
against T:G mismatches, despite the structur-
al similarity between T and U, perhaps be-
cause of the danger of T removal. By meth-
ylating C, however, the problem is recreated,
as deamination once more generates a normal
DNA base whose excision may be problem-
atic. Inefficient correction of the resulting
T:G mismatches may represent a compromise
between the benefits of repair and the damage
that could arise by removal of legitimate T
residues.
In conclusion, we have shown that murine
MBD4 suppresses CpG3 TpG mutations in
both a bacteriophage-based transgene and at
the endogenous Apc gene locus. These find-
ings suggest that human MBD4 plays a sim-
ilarly important role in reducing inherited
disease and cancer.
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A Role for Peroxisomes in
Photomorphogenesis and
Development of Arabidopsis
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The nuclear protein DET1 is a central repressor of photomorphogenesis in plants.
We have identified the molecular lesion in ted3, a mutation that dominantly
suppresses the phenotypes of det1-1. TED3 encodes a peroxisomal protein
(AtPex2p) essential for Arabidopsis growth. Developmental defects and the ab-
normal expression of many genes in det1 are rescued by ted3. ted3 also partially
suppresses another pleiotropic de-etiolated mutant cop1. Thus, peroxisomes,
whose functions are still largely unexplored, play a key role in a photomorpho-
genetic pathway negatively regulated by the DET1 and COP proteins.
Plants use sophisticated signal transduction
systems to sense and respond to environmen-
tal variation. The light signaling network, for
example, consists of a complex web of inter-
actions between multiple photoreceptors, ear-
ly signaling factors, and central integrators to
control the expression of hundreds of respon-
sive genes (1). The Arabidopsis DET1, COP,
and FUS proteins are proposed to be global
repressors of photomorphogenesis, because
their loss-of-function mutants develop as
light-grown plants in the absence of light (2).
Dark-grown det1 mutants have short hypoco-
tyls, opened cotyledons, and developed chlo-
roplasts and ectopically express many light-
regulated genes (3). They also exhibit stress
symptoms, such as anthocyanin accumulation
and aberrant expression of stress-related
genes. Light-grown det1 plants exhibit gen-
eral growth defects, such as small, pale-green
leaves and seedling lethality in strong alleles
(3). DET1 encodes a 62-kD nuclear protein
that regulates gene expression (4), yet its
precise mechanism of action is still unknown.
To better understand how DET1 exerts its
functions on photomorphogenesis and devel-
opment, we identified several extragenic sup-
pressors of det1-1, an intermediate-strength
allele that is impaired in the splicing of intron
1 but still produces 2% of wild-type
mRNA, and named them ted mutants. ted3 is
a dominant suppressor of det1 phenotypes
that does not correct the splicing defect of
det1-1 (5).
We fine-mapped the TED3 gene to a
130-kb region at the bottom of chromo-
some 1 (Fig. 1A). Sequencing of selected
open reading frames (ORFs) in this interval
in ted3 revealed a mutation in an ORF with
333 amino acids (GenBank accession number
AAG52254). Sequence comparison between
the genomic fragment and the corresponding
expressed sequence tag (EST) clone
(N96573) suggested that this gene has eight
exons (Fig. 1A) and encodes a 38-kD protein.
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